Form 4: Disc Medicine CLO Sells Shares Under 10b5-1 Plan

Disc Medicine's Chief Legal Officer, Rahul Khara, exercised stock options and sold 1,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Rahul Khara, Chief Legal Officer of Disc Medicine, Inc., engaged in a pre-planned transaction on January 20, 2026.
• Khara exercised stock options to acquire 1,000 shares of common stock at an exercise price of $13.50 per share.
• Concurrently, Khara sold 1,000 shares of common stock at a price of $69.74 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Khara directly beneficially owns 37,793 shares of common stock and 21,270 stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction under a 10b5-1 plan, which is generally neutral. The fact that the officer realized a significant profit from the option exercise and sale indicates positive stock performance for the company, but the sale itself slightly reduces insider ownership.

Positives

• The Chief Legal Officer realized a significant profit from exercising options at $13.50 and selling shares at $69.74, indicating a substantial increase in the company's stock value since the options were granted.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale was not based on new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the officer's direct equity stake in the company.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing, which solely details an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing, which is solely for reporting insider transactions.

Industry Context

This filing details a routine insider transaction under a pre-arranged trading plan, which is a common practice among executives in publicly traded companies across various industries to manage their equity holdings and diversify their portfolios while complying with insider trading regulations. It does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction (option exercise and sale) executed under a Rule 10b5-1 plan. Such plans are widely used by executives in public companies, including those in the biotech industry, to mitigate concerns about insider trading.
• The transaction itself does not offer a basis for comparison to specific company projects or results, but rather reflects a common mechanism for executive compensation and personal financial management.

Stakeholder Impact

• Shareholders: The sale by a Chief Legal Officer, even under a 10b5-1 plan, might be viewed with slight caution, but the pre-planned nature mitigates concerns about opportunistic selling. The profit realized by the officer reflects positively on the company's stock performance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The remaining 21,270 stock options held by Rahul Khara will continue to vest in equal monthly installments following December 29, 2022, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Legal Officer exercised options and sold shares under a pre-arranged 10b5-1 plan. While the officer realized a substantial profit, indicating positive past stock performance, the transaction itself is a standard part of executive compensation and personal financial management. It does not provide new fundamental information about the company's operations, financial health, or future prospects that would warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as investors should rely on broader company fundamentals rather than this specific insider transaction.

Keywords

Disc Medicine, IRON, Rahul Khara, Chief Legal Officer, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Equity Transaction